Court upholds HRSA's 340B Orphan interpretive rule

The U.S. District Court for the District of Columbia upheld an interpretive rule allowing discounts for Orphan drugs under Medicare's 340B program when used for non-Orphan indications. The Pharmaceutical Research and Manufacturers of America (PhRMA) had asked the court to vacate the rule, which was issued in July by HHS's Health Resources and Services Administration (HRSA). ...